CALT News and Press, Calliditas Therapeutics AB From 10/21/22

Calliditas Therapeutics' nomination committee composition for the AGM 2023 PR Newswire Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2023. STOCKHOLM , Oct. 21, 2022 /PRNewswire/ -- The nominatio...

Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA Nephropathy PR Newswire STOCKHOLM , Oct. 19, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("C...

Summary The key catalyst for Travere in the near term is the PDUFA date for sparsentan for the treatment of IgA nephropathy in early November. With a positive outcome anticipated, there might not be enough reward to hold the stock into the event. Given the recent slow launches...

Calliditas' partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathy PR Newswire STOCKHOLM , Sept. 20, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") toda...

Summary Shares have risen by 50% since coming public via reverse merger in 2020. Lead drug atrasentan has shown promising reductions in proteinuria that exceed approved treatment Tarpeyo. Competition in IgAN should not be underestimated from the likes of Travere Therapeutics, ...

Calliditas Therapeutics press release ( NASDAQ: CALT ): Q2 GAAP EPS of -SEK 3.62. Revenue of SEK 64M. Cash amounted to SEK 846.8M and SEK 709.3M as of June 30, 2022 and 2021 respectively. For further details see: Calliditas Therapeutics GAAP EPS of ...

Calliditas Therapeutics: Interim Report Q2, 2022 PR Newswire STOCKHOLM , Aug. 18, 2022 /PRNewswire/ -- European approval for Kinpeygo® "On May 19th , the European Medicines Agency (EMA) announced that it had adopted a positive opinion...

Results from the APOLLO-B study are due any day now and will significantly impact sentiment around ALNY shares, as well as the revenue potential of Onpattro. A clearly successful outcome could quadruple revenue, but it's possible that the trial could meet its primary outcome and fail ...

Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics PR Newswire Kinpeygo® (developed under the name NEFECON) is the first and only EMA- approved treatment ...

The European Commission has approved Calliditas Therapeutics' ( NASDAQ: CALT ) Kinpeygo (budesonide) for the treatment of immunoglobulin A (IgA) nephropathy in adults. Shares are up 9% in Friday afternoon trading. The drug was developed under the name Nefe...